Jonathan Hunt

Biocon's contract research arm Syngene International today posted 54.02 per cent rise in its net profit at Rs 74.7 crore for the second quarter ended September 30, driven by discovery and R&D centre business verticals.

Will scale up contract mfg; $200 mn capex for key arms: Syngene

Of USD 200 million capex, USD 100 million will go into four key areas- Syngene Research Centre, biologic centre, formulation center, viral testing and the rest in commercial manufacturing, says Jonathan Hunt, CEO of Syngene International.

Syngene Q4 net profit soars 20% to Rs 66 cr

Biocon's contract research arm Syngene International today reported a 19.6 percent rise in standalone net profit at Rs 66.5 crore for March quarter.

Syngene appoints Jonathan Hunt as CEO-designate

In his new role Hunt would be responsible for strengthening Syngene's relations with its existing global customers as well as forging new relationships, the company said.